There’s been a few new biotech or biotech-related funds that have made announcements recently. Let’s take a look…

• First, BioMed Realty Trust, Inc. has closed a $350 million loan with John Hancock Life Insurance Company, TIAA-CREF, and Westdeutsche ImmobilienBank AG. The five year loan is secured by a single property – the Center for Life Science I Boston, a newly constructed 700,000+ sq. ft. state-of-the-art research facility that recently received Gold LEED certification from the U.S. Green Building Council. BioMed Realty Trust focuses on “acquiring, developing, owning and operating world-class research facilities in the core life science markets.” [MarketWatch]

• Next, Novo Growth Equity, an investment activity of Novo A/S, announced last week that it has expanded its leadership team in Copenhagen. Additionally, the group will invest up to $200 million (USD) annually into promising later stage and commercially viable life science companies. [Company Press Release]

• Finally, Israel is setting up a capital fund of up to 1 billion shekels ($255 million) to finance biotechnology start-ups. The state would contribute some 250 million shekels to the fund which it hopes to rise to 1 billion shekels using loans from private investors. The aim is to encourage and advance growth in Israel’s biotech sector. [Reuters]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts